Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

NCT04903119 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma
BRAF Gene Mutation

Interventions

DRUG: Nilotinib 100mg
DRUG: Nilotinib 200mg
DRUG: Nilotinib 300mg
DRUG: Nilotinib 400mg
DRUG: Dabrafenib
DRUG: Trametinib
DRUG: Encorafenib
DRUG: Binimetinib

Sponsor

Rina Plattner

Collaborators

[object Object]
[object Object]